Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANTX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
ANTX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

ANTX Similar Chart Price Prediction

The price of ANTX is predicted to go up 2.31%, based on the high correlation periods with DLTH. The similarity of these two price pattern on the periods is 95.84%.

stocks logo

ANTX

stocks logo

DLTH

Up: 2.31%Similarity: 95.84%

ANTX Revenue Forecast

ANTX EPS Forecast

ANTX FAQs

What is bull’s view on ANTX?

ANTX stock has bullish potential with a price target of $5, as reiterated by JMP Securities on November 19, 2024. This optimism stems from the promising pipeline, particularly in treatments for Chagas disease and melioidosis, which address significant unmet medical needs. Despite recent insider sales and mixed institutional sentiment, the long-term growth prospects in rare infectious diseases support a positive outlook.

What is bear's view on ANTX?

ANTX stock currently trades at $1.13, reflecting a bearish sentiment due to disappointing Phase 2 trial results for its drug epetraborole and mixed institutional activity. Analysts have downgraded the stock, with a price target as low as $1.00, citing limited near-term catalysts despite potential in its pipeline. Insider selling and reduced institutional positions further reinforce the negative outlook.

ANTX VS S&P500

Ask Intellectia about ANTX

ANTX Analyst's Forecast

Ritu Baral

TD Cowen

Strong Buy → Hold

Price Target

n/a

Upside

0%

TD Cowen downgraded AN2 Therapeutics to Hold from Buy without a price target. The Phase 2 EBO topline data in non-tuberculous mycobacterial saw no difference in culture conversion, the analyst tells investors in a research note. The firm says that while AN2 is evaluating restarting the Phase 3 EBO trial pending an FDA talk in the first half of 2025, it has "conservative expectations."
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free